Tramadol: A review of this atypical opioid

European Journal of Palliative Care

Volumn 14, Issue 5, 2007, Pages 181-185

  Dickman, Andrew ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34748878869     PISSN: 13522779     EISSN: 14790793     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. IMS Health Inc. IMS Chemical Kilochem Profile and IMS Midas, 1994-2005.
2. Arbaiza D, Vidal O. Tramadol in the treatment of neuropathic cancer pain. Clin Drug Investig 2007; 27: 75-83.
3. Mercadante S, Arcurl E, Fusco F et al. Randomized double-blind, double-dummy crossover clinical trial of oral tramadol versus rectal tramadol administration in opioid-naive cancer patients with pain. Support Care Cancer 2005; 13: 702-707.
4. Grond S, Radbruch L, Meuser T et al. High-dose tramadol in comparison to low-dose morphine for cancer pain relief. J Pain Symptom Manage 1999; 18: 174-179.
5. Hollingshead J, Duhmke RM, Cornblath DR. Tramadol for neuropathic pain. Cochrane Database Syst Rev 2006; 3(Jul 19): CD003726.
6. Raffa RB, Friderichs E, Reimann W et al. Complementary and synergistic antinociceptive interaction between the enantiomers of tramadol. J Pharmacol Exp Ther 1993; 267: 331-340.
7. Bamigbade TA, Davidson C, Langford RM, Stamford JA. Actions of tramadol, its enantiomers and principal metabolite, O-desmethyltramadol, on serotonin (5-HT) efflux and uptake in the rat dorsal raphe nucleus. Br J Anaesth 1997; 79: 352-356.
8. Ide S, Minami M, Ishihara K et al. Mu opioid receptor-dependent and independent components in effects of tramadol. Neuropharmacology 2006; 51: 651-658.
9. Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet 2004; 43: 879-923.
10. Lintz W, Beier H, Gerloff J. Bioavailability of tramadol after IM injection in comparison to IV infusion. Int J Clin Pharmacol Ther 1999, 37: 175-183.
11. Pedersen RS, Damkier P, Brosen K. Enantioselective pharmacokinetics of tramadol in CYP2D6 extensive and poor metabolizers. Eur J Clin Pharmacol 2006; 62: 513-521.
12. Poulsen L, Arendt-Nielsen L, Brosen K, Sindrup SH. The hypoalgesic effect of tramadol in relation to CYP2D6. Clin Pharmacol Ther 1996; 60: 636-644.
13. Paar WD, Poche S, Gerloff J, Dengler HJ. Polymorphic CYP2D6 mediates O-demethylation of the opioid analgesic tramadol. Eur J Clin Pharmacol 1997; 53: 235-239.
14. Subrahmanyam V, Renwick AB, Walters DG et al. Identification of cytochrome P-450 isoforms responsible for cis-tramadol metabolism in human liver microsomes. Drug Metab Dispos 2001; 29: 1146-1155.
15. Paar WD, Frankus P, Dengler HJ. The metabolism of tramadol by human liver microsomes. Clin Investig 1992; 70: 708-710.
16. Desmeules JA, Piguet V, Collart L, Dayer P. Contribution of monoaminergic modulation to the analgesic effect of tramadol. Br Jr Clin Pharmacol 1996; 41: 7-12.
17. Oliva P, Aurilio C, Massimo F et al. The antinociceptive effect of tramadol in the formalin test is mediated by the serotonergic component. Eur J Pharmacol 2002; 445: 179-185.
18. Rojas-Corrales MO, Ortega-Alvaro A, Gibert-Rahola J et al. Pindolol, a beta-adrenoceptor blocker/5-hydroxytryptamine(1A/1B) antagonist, enhances the analgesic effect of tramadol. Pain 2000; 88: 119-124.
19. Berrocoso E, Mico JA, Ugedo L. In vivo effect of tramadol on locus coeruleus neurons is mediated by alpha2-adrenoceptors and modulated by serotonin. Neuropharmacology 2006; 51: 146-153.
20. Raffa RB, Friderichs E, Reimann W et al. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic. J Pharmacol Exp Ther 1992; 260: 275-285.
21. Grond S, Meuser T, Zech D, Hennig U, Lehmann KA. Analgesic efficacy and safety of tramadol enantiomers in comparison with the racemate: a randomised, double-blind study with gynaecological patients using intravenous patient-controlled analgesia. Pain 1995; 62: 313-320.
22. Garlicki J, Dorazil-Dudzik M, Wordliczek J, Przewlocka B. Effect of Intraarticular tramadol administration in the rat model of knee joint inflammation. Pharmacol Rep 2006; 58: 672-679.
23. Buccellati C, Sala A, Ballerio R, Blanchib M. Tramadol anti-inflammatory activity is not related to a direct inhibitory action on prostaglandin endoperoxide synthases. Eur J Pain 2000; 4: 413-415.
24. Bianchi M, Broggini M, Balzarini P et al. Effects of tramadol on synovial fluid concentrations of substance P and interleukin-6 in patients with knee osteoarthritis: comparison with paracetamol. Int Immunopharmacol 2003; 3: 1901-1908.
25. Lui HC, Zhang XJ, Yang YY, Wang N, Hou YN. Stereoselectivity in renal clearance of trans-tramadol and its active metabolite, trans-O-desmethyltramadol. Acta Pharmacol Sin 2002; 23: 83-86.
26. Slanar O, Nobilis M, Kvetina J et al. Pharmacokinetics of tramadol is affected by MDR1 polymorphism C4345T. Eur J Clin Pharmacol 2007; 63: 419-421.
27. Sachse C, Brockmoller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997; 60: 284-295.
28. Stamer UM, Bayerer B, Stüber F. Genetics and variability in opioid response. Eur J Pain 2005; 9: 101-104.
29. Abdel-Rahman SM, Leeder JS, Wilson JT et al. Concordance between tramadol and dextromethorphan parent/metabolite ratios: the influence of CYP2D6 and non-CYP2D6 pathways on biotransformation. J Clin Pharmacol 2002; 42: 24-29.
30. Stamer UM, Lehnen K, Hothker F et al. Impact of CYP2D6 genotype on postoperative tramadol analgesia. Pain 2003; 105: 231-238.
31. Wang G, Zhang H, He F, Fang X. Effect of the CYP2D6* 10 C188T polymorphism on postoperative tramadol analgesia in a Chinese population. Eur J Clin Pharmacol 2006; 62: 927-931.
32. Samer CF, Desmeules JA, Dayer P. Individualizing analgesic prescription. Part I: pharmacogenetics of opioid analgesics. Personalized Medicine 2006; 3: 239-269.
33. Zydol 50mg capsules [Grünenthal Ltd - Summary of Product Characteristics]. Surrey: Datapharm Communications Ltd; 2007. Available at: http://emc.medicines.org.uk (last accessed 5 March 2007)
34. Laugesen S, Enggaard TP, Pedersen RS, Sindrup SH, Brosen K. Paroxetine, a cytochrome P450 2D6 inhibitor, diminishes the stereoselective O-demethylation and reduces the hypoalgesic effect of tramadol. Clin Pharmacol Ther 2005; 77: 312-23.
35. Mittino D, Mula M, Monaco F. Serotonin syndrome associated with tramadol-sertraline coadministration. Clin Neuropharmacol 2004; 27: 150-151.
36. Kesavan S, Sobala GM. Serotonin syndrome with fluoxetine plus tramadol. J R Soc Med 1999; 92: 474-475.
37. Mahlberg R, Kunz D, Sasse J, Kirchheiner J. Serotonin syndrome with tramadol and citalopram. Am J Psychiatry 2004; 161: 1129.
38. Houlihan DJ. Serotonin syndrome resulting from coadministration of tramadol, venlafaxine and mirtazapine. Ann Pharmacother 2004; 38: 411-413.
39. Arcioni R, della Rocca M, Romano S et al. Ondansetron inhibits the analgesic effects of tramadol: a possible 5-HT(3) spinal receptor involvement in acute pain in humans. Anesth Analg 2002; 94: 1553-1557.
40. Pang WW, Wu HS, Lin CH, Chang DP, Huang MH. Metoclopramide decreases emesis but increases sedation in tramadol patient-controlled analgesia. Can J Anaesth 2002; 49: 1029-1033.
41. Barann M, Urban B, Stamer U et al. Effects of tramadol and O-demethyl-tramadol on human 5-HT reuptake carriers and human 5-HT3A receptors: a possible mechanism for tramadol-induced early emesis. Eur J Pharmacol 2006; 531: 54-58.
42. Petrone D, Kamin M, Olson W. Slowing the titration rate of tramadol HCl reduces the incidence of discontinuation due to nausea and/or vomiting: a double-blind randomized trial. J Clin Pharm Ther 199; 24: 115-123.
43. Ruoff GE. Slowing the initial titration rate of tramadol improves tolerability. Pharmacotherapy 1999; 19: 88-93.
44. Tagarro I, Herrera J, Barutell C et al. Effect of a simple dose-escalation schedule on tramadol tolerability: assessment in the clinical setting. Clin Drug Investig 2005; 25: 23-31.
45. Gasse C, Derby L, Vasilakis-Scaramozza C, Jick H. Incidence of first-time idiopathic seizures in users of tramadol. Pharmacotherapy 2000; 20: 629-634.
46. Adams EH, Breiner S, Cicero TJ et al. A comparison of the abuse liability of tramadol, NSAIDs, and hydrocodone in patients with chronic pain. J Pain Symptom Manage 2006; 31: 465-476.
47. Twycross R, Wilcock A, Charlesworth S, Dickman A. Palliative Care Formulary, 2nd edn. Abingdon: Radcliffe Medical Press, 2002.